Lipid-Linked dsCpG Oligonucleotide for Stable Immunostimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Double-stranded CpG oligonucleotides (dsCpG ODN) lack immunostimulatory activity when administered alone and are prone to rapid degradation, leading to reduced efficacy as vaccine adjuvants, whereas encapsulation in lipofectin particles shows immunostimulatory activity but with unclear mechanisms.
Innovation Solution
Development of a lipid-binding double-stranded oligonucleotide where a first strand is a CpG oligonucleotide and a second strand binds to a lipid through a linker, enhancing antigen-specific CTL induction and showing anti-tumor effects, with improved metabolic stability and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If double-stranded CpG oligonucleotides are administered alone, then they are stable in structure, but they lack immunostimulatory activity and show reduced efficacy as vaccine adjuvants
Solution Approach 1:
The double-stranded oligonucleotide is segmented into a first strand (CpG oligonucleotide) and a second strand (complementary oligonucleotide), where only the first strand contains the immunostimulatory CpG motif. This segmentation allows the molecule to maintain structural stability while preserving immunostimulatory activity through the unmethylated CpG dinucleotide sequence in the first strand that can still be recognized by TLR9.
Solution Approach 2:
The invention creates a composite structure combining a CpG-containing oligonucleotide first strand with a complementary second strand. This composite double-stranded structure provides both structural stability and immunostimulatory activity, as the first strand's CpG motif remains accessible for immune recognition while the second strand provides structural support.
2Object-generated harmful factors
If single-strand CpG oligonucleotides are used, then they show strong immunostimulatory activity, but they suffer from poor in vivo stability and rapid degradation
Solution Approach 1:
The invention merges the immunostimulatory single-stranded CpG oligonucleotide with a complementary second strand to form a double-stranded structure. This combination preserves the immunostimulatory activity of the CpG motif while the double-stranded configuration protects against rapid degradation by nucleases, thereby improving in vivo stability.
Solution Approach 2:
The second strand acts as a protective shell or coating around the immunostimulatory first strand. This protective layer shields the CpG motif from enzymatic degradation while allowing immune recognition, similar to how a flexible shell protects an internal structure while maintaining functionality.
3Object-generated harmful factors
If ssCpG ODN is encapsulated in lipofectin particles, then immunostimulatory activity is restored, but the mechanism is unclear and device complexity increases
Solution Approach 1:
The invention extracts the protective function from the complex lipofectin particle encapsulation system and integrates it directly into the oligonucleotide structure itself by forming a double-stranded configuration. This eliminates the need for external encapsulation while maintaining protection against degradation and preserving immunostimulatory activity.
Solution Approach 2:
The second complementary strand serves as an intermediary that mediates both structural protection and immunostimulatory function. Rather than using complex external encapsulation, the second strand acts as an internal mediator that stabilizes the first strand while allowing its CpG motif to remain accessible for immune recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid-binding double-stranded oligonucleotide demonstrates strong immunostimulatory activity, enhanced CTL inducibility, and anti-tumor effects with high metabolic stability and low toxicity, making it suitable as a vaccine adjuvant or cancer vaccine.
Implementation Method 1
a second strand binds to a lipid through a linker
Implementation Method 2
a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand
Data Source
AI summary
The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity.An adjuvant comprising a double-stranded oligonucleotide, whereina first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides,a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprisinga sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.